blincyto-blinatumomab-wholesaler

Blincyto (Blinatumomab)

June 28, 2018
Off
Back to Catalog
  • « Back to Catalog
  • Blinatumomab
    Monoclonal antibody
    Type Bi-specific T-cell engager
    Source Mouse
    Target CD19, CD3
    Clinical data
    Trade names Blincyto
    Synonyms AMG103, MT103
    License data
    • EU EMA: by INN
    Pregnancy
    category
    • US: C (Risk not ruled out)
    Routes of
    administration    		 intravenous
    ATC code
    • L01XC19 (WHO)
    Legal status
    Legal status
    • US: ℞-only
    Pharmacokinetic data
    Bioavailability 100% (IV)
    Metabolism degradation into small peptides and amino acids
    Elimination half-life 2.11 hours
    Excretion urine (negligible)
    Identifiers
    CAS Number
    • 853426-35-4 No
    DrugBank
    • DB09052 Yes
    ChemSpider
    • none
    UNII
    • 4FR53SIF3A
    KEGG
    • D09325
    Chemical and physical data
    Formula C2367H3577N649O772S19
    Molar mass 54.1 kg/mol
     NoYes (what is this?)  (verify)

    Blinatumomab (trade name Blincyto) is a biopharmaceutical drug used as a second-line treatment for Philadelphia chromosome-negative relapsed or refractory acute lymphoblastic leukemia.

Comments are closed.